Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo
about
Modulating Dickkopf-1: A Strategy to Monitor or Treat Cancer?The osteocyte as a therapeutic target in the treatment of osteoporosisPotential role for therapies targeting DKK1, LRP5, and serotonin in the treatment of osteoporosisDickkopf-1 regulates bone formation in young growing rodents and upon traumatic injuryA genome-wide association study in Han Chinese identifies new susceptibility loci for ankylosing spondylitisKremen1 and Dickkopf1 control cell survival in a Wnt-independent mannerEffects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy SeriesGremlin1 is required for skeletal development and postnatal skeletal homeostasisWnt signaling and orthopedics, an overviewHigh-throughput screening of mouse gene knockouts identifies established and novel skeletal phenotypes.Chemical and genetic evidence for the involvement of Wnt antagonist Dickkopf2 in regulation of glucose metabolism.Targeting Wnt pathways in disease.Immunogenetic study in Chinese population with ankylosing spondylitis: are there specific genes recently disclosed?Wnt signaling in bone formation and its therapeutic potential for bone diseases.Regulatory pathways associated with bone loss and bone marrow adiposity caused by aging, chemotherapy, glucocorticoid therapy and radiotherapy.LRP5 and bone mass regulation: Where are we now?Functional Characterization of a Small-Molecule Inhibitor of the DKK1-LRP6 InteractionEstrogen regulation of Dkk1 and Wnt/β-Catenin signaling in neurodegenerative disease.An unexpected role for a Wnt-inhibitor: Dickkopf-1 triggers a novel cancer survival mechanism through modulation of aldehyde-dehydrogenase-1 activity.Wnt proteins in mineralized tissue development and homeostasis.Osteoblastogenesis regulation signals in bone remodeling.Systemic effects of Wnt signaling.Fat and bone interactions.Biological agents in management of osteoporosis.Osteocytic signalling pathways as therapeutic targets for bone fragility.New Target Sites for Treatment of Osteoporosis.Evaluation of the effects of systemic treatment with a sclerostin neutralizing antibody on bone repair in a rat femoral defect model.Osteoblast as a target of anti-osteoporotic treatment.Homozygous Dkk1 Knockout Mice Exhibit High Bone Mass Phenotype Due to Increased Bone Formation.Vaccination with DKK1-derived peptides promotes bone formation and bone mass in an aged mouse osteoporosis model.Peptide-based mediated disruption of N-cadherin-LRP5/6 interaction promotes Wnt signaling and bone formation.Effects of iguratimod on the levels of circulating regulators of bone remodeling and bone remodeling markers in patients with rheumatoid arthritis.
P2860
Q26745556-BD426EBF-912E-4C64-9280-4AB2CE8A8DB7Q27009129-188346C9-49C5-4A06-AC93-84EACDC37569Q28256427-A5640F58-EB51-4EE1-8BAE-731B6A3F738DQ28584092-86B22373-85B4-4AB3-BB80-DD7A4BA6652DQ28943358-50AA5316-7DC8-484A-B78E-A568B3AAF3B7Q28975609-2E3FD0E0-4D11-49DF-92A3-D5442557C148Q30532494-148C2808-6E35-4075-BD5B-FA4FF5E105CEQ35093489-2E6EF970-D5E6-4B72-9AED-A56DC476377CQ35605991-154DF8FD-F273-45CA-8831-2F3D515F0BB8Q35755147-489EC75F-FEFE-4513-92EE-25284EB91ACCQ36094201-E423AB69-ED38-4236-88B0-1410BB06E1D0Q36506697-CD947CA0-F533-4C9E-87FD-DE0ACC4DC107Q36582625-9CB83083-9451-4446-9BBC-CC609DFF750CQ36638647-D2EA6D05-1926-4521-9020-0E6A04629C9AQ36796392-1366AD11-EE2F-4542-9569-20499EF1DEC0Q36995895-24A43826-D487-4E24-83C1-3F6640D5EF0EQ37005265-17A49294-5E9E-4737-B512-852D9240AEA5Q37241063-E5B45C92-AED8-48FA-A898-09D7E4C39143Q37620723-A562199A-5090-4743-B1DB-3DC0C0DBF25EQ37943458-A0A3CC6E-9D5C-4ADA-8076-472CE9BB9DA9Q37980021-060281ED-C4A3-4064-95E2-4939675BC4B4Q38077507-3B03D2E3-18CB-4878-9D71-72CBF6A24AC8Q38193721-419755D7-E068-4256-95CD-D1A1C9029CDCQ38247465-9952682B-7E30-46C9-9483-A2DF9E91FF5DQ38845640-61CF4850-EC20-4C05-AF92-7935CD12AC36Q39151180-7DE35394-CD60-446B-ACB8-99FACEE8944EQ45987051-814471F2-B5B8-4509-A065-2395B3333FAEQ47996918-348FC095-CB16-449D-8C51-E1F22A1C179EQ50145648-106DAC70-34BD-4D00-AA1C-9BE8DD2CAEEBQ51135494-C4D7A303-807C-4D27-8FA1-F15AD7E555B7Q52625208-E7B311CA-4684-4DB9-B252-DB539CB6D7ACQ54014686-3D756613-8FBE-4657-A84C-874954E15275
P2860
Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Generation and selection of no ...... and increase bone mass in vivo
@ast
Generation and selection of no ...... and increase bone mass in vivo
@en
type
label
Generation and selection of no ...... and increase bone mass in vivo
@ast
Generation and selection of no ...... and increase bone mass in vivo
@en
prefLabel
Generation and selection of no ...... and increase bone mass in vivo
@ast
Generation and selection of no ...... and increase bone mass in vivo
@en
P2093
P2860
P356
P1476
Generation and selection of no ...... and increase bone mass in vivo
@en
P2093
Alfred A Reszka
Cheryl Ireland
Donald Kimmel
Fabio Talamo
Fubao Wang
Helmut Glantschnig
Jing Z Zhao
John E Fisher
Kevin R Scott
Laura Orsatti
P2860
P304
40135-40147
P356
10.1074/JBC.M110.166892
P407
P577
2010-10-07T00:00:00Z